Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

TY - JOUR

T1 - Effect of anti–tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis—A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

AU - Syed, Maha N.

AU - Shah, Mohsin

AU - Shin, Daniel B.

AU - Wan, Marilyn T.

AU - Winthrop, Kevin L.

AU - Gelfand, Joel M.

N1 - Funding Information: Funding sources: Supported in part by a grant ( P30AR069589-03 ) from the National Institutes of Health (to Dr Gelfand). Funding Information: Disclosure: Dr Syed is supported in part by a grant from Pfizer . Dr Shah is supported by a National Institutes of Health –funded T-32 postdoctoral fellowship. Dr Wan is supported in part by a grant from Pfizer . Dr Winthrop receives grants from Bristol Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), Sanofi, and Pfizer, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie , Janssen , Novartis , Sanofi , Celgene , Ortho Dermatologics , and Pfizer ; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics ; is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare. Funding Information: Funding sources: Supported in part by a grant (P30AR069589-03) from the National Institutes of Health (to Dr Gelfand).Disclosure: Dr Syed is supported in part by a grant from Pfizer. Dr Shah is supported by a National Institutes of Health?funded T-32 postdoctoral fellowship. Dr Wan is supported in part by a grant from Pfizer. Dr Winthrop receives grants from Bristol Myers Squibb and Pfizer and is a consultant for UCB, AbbVie, Lilly, Bristol Myers Squibb, Pfizer, GlaxoSmithKline, and Roche. Dr Gelfand served as a consultant for Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis Corp, Regeneron, UCB (data safety and monitoring board), Sanofi, and Pfizer, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis, Sanofi, Celgene, Ortho Dermatologics, and Pfizer; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics; is a copatent holder of resiquimod for treatment of cutaneous T-cell lymphoma; and is a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology. Dr Shin has no conflicts of interest to declare.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85096168720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096168720&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2020.08.095

DO - 10.1016/j.jaad.2020.08.095

M3 - Article

C2 - 32860913

AN - SCOPUS:85096168720

SN - 0190-9622

VL - 84

SP - 161

EP - 163

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -